ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO0033

Kidney Biopsy Findings in AKI in the Cohort of Patients of Mexico Tertiary Hospital

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention

Authors

  • Martinez-Vazquez, Belen, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, Estado de Mexico, Mexico
  • Moguel, Bernardo, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, Estado de Mexico, Mexico
  • Soto, Virgilia, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, Estado de Mexico, Mexico
  • Garcia-Flores, Octavio Rene, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, Estado de Mexico, Mexico
Background

The study of the epidemiology of biopsy-confirmed renal disease provides useful information about the prevalence of renal disease and its clinical manifestations.
Performing a kidney biopsy is necessary to accurately diagnose diseases such as glomerulonephritis and tubulointerstitial nephritis, among other such conditions
Kidney biopsy in acute kidney injury (AKI) of unknown origin provides irreplaceable information for diagnosis, treatment, and prognosis. In this report, we analyze the frequency and clinicopathologic correlations of renal native biopsied AKI in Mexican cohort during the period 2014 through 2019.

Methods

We analyzed the frequency and clinicopathologic correlations of AKI confirmed by native renal biopsy in Mexico tertiary hospital and the distribution of the different clinicopathologic findings. From 2014-2019 period, totally 515 patients first received renal biopsy.
AKI was diagnosed based on the Kidney Disease: Improving Global Outcomes criteria.

Results

Of the 515 patients investigated, 200 (38.8%) showed AKI. Of these, 102 (51%), 47 (23.5%), and 51 (25.5%) presented with AKI classified as stages 1, 2, and 3, respectively. The primary indication for performing biopsy was rapidly progressive glomerulonephritis (RPGN) in 70 (35%) and nephrotic syndrome in 47 (23.5%). Dialysis previous kidney biopsy was necessary in 48 patients (24%). Focal segmental glomerulosclerosis was the most prevalent primary disease in 37 (18.5%) and lupus nephritis wast the most prevalent secondary disease in 53 (26.5%). In the early patients the most prevalent disease was pauci-immune rapidly progressive GN
Multivariate analysis of risk factors associated with AKI showed hemoglobin levels (OR 0.800, 95% confidence interval [CI] 0.671–0.941, p=0.01), dialysis previous kidney biopsy (OR 3.970, 95% CI 2.949–4.392, p=0.008), and baseline serum creatinine levels (OR 2.402, 95% CI 1.371–4.758, p=0.001) were significantly associated with AKI.

Conclusion

We observed a high prevalence of AKI in patients who underwent kidney biopsy to investigate their renal disease, particularly glomerulonephritis. The prevalence of vasculitis and crescentic GN is high, especially in elderly patients.